Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Black Stone Minerals, L.P.
BSM·Energy
B ★★★Hold
Current$14.40
Target$16.50
Return+14.6%
Nov 5, 2026

Black Stone Minerals offers attractive cash distributions and capital-efficient royalty growth through diversified U.S. mineral ownership, but commodity-price exposure and an elevated historical cash-flow multiple limit the margin of safety.

Score
70
Janus Living, Inc.
JAN·Real Estate
B ★★★Hold
Current$30.07
Target$33.60
Return+11.7%
Nov 5, 2026

Janus Living offers exposure to accelerating senior housing demand through acquisitions and improving property economics, but its premium FFO valuation and recurring equity financing limit the margin of safety.

Score
70
Axsome Therapeutics, Inc.
AXSM·Healthcare
B ★★★Hold
Current$137.00
Target$176.67
Return+29.0%
Nov 5, 2026

Axsome's expanding neuroscience franchise and strong AUVELITY prescription growth support substantial long-term revenue opportunities, but product concentration, clinical uncertainty, and continued cash burn limit near-term investment conviction.

Score
70
Cabot Corporation
CBT·Materials
B ★★★Hold
Current$75.10
Target$80.63
Return+7.4%
Nov 5, 2026

Cabot combines a defensible global carbon-materials franchise with growing battery-additive opportunities at a reasonable valuation, but reinforcement pricing pressure and weaker free cash flow may constrain near-term returns.

Score
70
LyondellBasell Industries N.V.
LYB·Materials
B ★★★Hold
Current$67.25
Target$79.02
Return+17.5%
Nov 2, 2026

LyondellBasell offers cyclical earnings recovery potential through cost-advantaged polymers, improving cash flow and portfolio optimization, but global oversupply and substantial debt could delay sustained value creation.

Score
70
Glaukos Corporation
GKOS·Healthcare
B ★★★Hold
Current$237.60
Target$208.45
Return-12.3%
Nov 2, 2026

Glaukos combines accelerating ophthalmic treatment adoption, differentiated clinical technology, and emerging profitability, but its premium valuation leaves limited room for commercialization or earnings disappointments.

Score
70
RingCentral, Inc.
RNG·Technology
B ★★★Hold
Current$81.42
Target$89.60
Return+10.0%
Nov 2, 2026

RingCentral's recurring cloud communications revenue, expanding margins, and AI monetization support further cash-flow growth, but intense competition, meaningful SBC, and a substantial stock-price recovery limit its margin of safety.

Score
70
Cousins Properties Incorporated
CUZ·Real Estate
B ★★★Hold
Current$29.55
Target$32.64
Return+10.5%
Nov 1, 2026

Cousins Properties offers a quality-focused Sun Belt office portfolio with improving leasing and recurring FFO, but structural office-demand uncertainty, capital intensity, and future dilution constrain its upside.

Score
70
Weyerhaeuser Company
WY·Real Estate
B ★★★Hold
Current$20.35
Target$24.30
Return+19.4%
Nov 1, 2026

Weyerhaeuser offers asset-backed upside from timberland ownership and a potential housing recovery, but weak current returns, elevated leverage, and insufficient recurring cash flow constrain the investment case.

Score
70
Exelixis, Inc.
EXEL·Healthcare
B ★★★Hold
Current$69.39
Target$65.45
Return-5.7%
Nov 1, 2026

Exelixis combines exceptional oncology cash generation and substantial buybacks with a promising second drug franchise, but CABOMETYX concentration and a historically elevated valuation limit the margin for regulatory disappointment.

Score
70
Quaker Chemical Corporation
KWR·Materials
B ★★★Hold
Current$150.95
Target$165.60
Return+9.7%
Nov 1, 2026

Quaker's specialized industrial fluids franchise offers recurring customer demand and recovery potential at historically moderate valuation multiples, but weak free cash flow and cyclical manufacturing exposure constrain near-term upside.

Score
70
Customers Bancorp, Inc.
CUBI·Financials
B ★★★Hold
Current$84.16
Target$95.00
Return+12.9%
Nov 1, 2026

Customers Bancorp combines rapid commercial lending growth, improving efficiency, and a valuable deposit franchise with reasonable forward earnings valuation, but credit-cycle exposure, shareholder dilution, and funding competition limit its margin of safety.

Score
70